Details of a new UK clinical trial to assess the risks and benefits of puberty-blocking drugs in children who question their gender have been announced. It follows the banning of the drugs for gender treatment last year after a major review raised concerns about the lack of clinical evidence over their safety for under-18s. Researchers from King's College London say the trial will involve around 220 children under the age of 16 who are going through puberty, and will examine the impact of the drugs on their physical, social and emotional wellbeing. Some clinicians and campaigners question whether the trial is ethical...